Synergistic innovation in organ-on-a-chip and organoid technologies: reshaping the future of disease modeling, drug development, and precision medicine
Peer-Reviewed Publication
Updates every hour. Last Updated: 31-Dec-2025 17:11 ET (31-Dec-2025 22:11 GMT/UTC)
FDA issued guidance on April 10, 2025 to phase out animal trials in favor of organoids and organ-on-a-chip systems. This pivotal move was swiftly followed by National Institutes of Health (NIH) on April 29, when it inaugurated the Office of Research Innovation, Validation, and Application (ORIVA).
An interdisciplinary research team lead by Harbin Institute of Technology has developed a multifunctional biphasic bone scaffold featuring a "steel-cement" structure using eggshells waste. This scaffold integrates a rigid lattice (biosteel) with a bioactive hydrogel (biocement) loaded with composite drug-releasing particles, facilitating anti-infective and osteogenic functions. With adjustable mechanical properties, biodegradability, and intelligent responsiveness, this scaffold demonstrates significant potential for precise, sustainable, and dynamic bone regeneration.
This study not only demonstrates the high-value transformation of waste biological resources but also provides new ideas for advancing bone regeneration toward intelligent and personalized therapeutic paradigms.
Compounds found in tea, coffee, berries and nuts linked to better long-term heart health.
A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with long-term side effects.